UC Davis Health Ventures invests in Delix Therapeutics for MDD treatment

Cardiff University celebrated the achievements of its growing entrepreneurial community at a special event showcasing research commercialisation and innovation. 👇 Full story in comments 👇 The event, 'From Research Innovation to Commercial Impact - Celebrating Cardiff University's Spinouts and Startups', which took place on 23 September at the St David’s Hotel, was attended by over 100 guests from across the policy, academic, civic and industry communities. The event was sponsored by the Wellcome Trust, and co-convened with the GW4. The event marked a public celebration of Draig Therapeutics, following its official launch in June. Draig Therapeutics, a Cardiff University spinout founded on the research and expertise of Professor John Atack and Professor Simon Ward from Cardiff University’s Medicines Discovery Institute, will translate the latest research to pioneer new therapies for neuropsychiatric conditions. #CardiffUniversity #PrifysgolCaerdydd | Draig Therapeutics

📣 We are excited to announce that Owlstone Medical has been awarded up to $49.1M from ARPA-H for our project within the POSEIDON program, a groundbreaking initiative to develop the first at-home multi-cancer early detection test (MCED). Throughout this program, we are proud to collaborate with Massachusetts Institute of Technology, Boston University, Georgia Tech Research, Qurin, and Planned Systems International. Why does it matter? Nearly 40% of Americans will face cancer in their lifetime. Detecting it early not only saves lives but could also reduce healthcare costs by trillions of dollars. Learn more about this development in our latest press release 👉 https://bit.ly/4nvM7YW #CancerDetection #HealthcareInnovation #EarlyDetection

Very exciting news today as Owlstone embarks on a major program funded by the U.S. Advanced Research Projects Agency for Health (ARPA-H) to detect 30+ cancers early. Here's our CEO Billy Boyle sharing more (click on Billy's comment to watch a video).

📣 We are excited to announce that Owlstone Medical has been awarded up to $49.1M from ARPA-H for our project within the POSEIDON program, a groundbreaking initiative to develop the first at-home multi-cancer early detection test (MCED). Throughout this program, we are proud to collaborate with Massachusetts Institute of Technology, Boston University, Georgia Tech Research, Qurin, and Planned Systems International. Why does it matter? Nearly 40% of Americans will face cancer in their lifetime. Detecting it early not only saves lives but could also reduce healthcare costs by trillions of dollars. Learn more about this development in our latest press release 👉 https://bit.ly/4nvM7YW #CancerDetection #HealthcareInnovation #EarlyDetection

This week on the show: After losing his father, Reed Jobs committed himself to making this the last generation that loses parents to the disease. Reed now leads Yosemite, a venture fund spun out of Emerson Collective in 2023, alongside Investor Matt Bettonville. Yosemite pairs life sciences and digital health investments with a grantmaking model to accelerate cancer research and ensure breakthroughs actually reach patients. We cover: 📉 The tension between drug pricing, patient access, and real-world value 🩺 Digital interventions that have outperformed cancer drugs in survival outcomes 🧪 Why phase 3 clinical trials are so costly, and how synthetic control arms could change that 🧬 The promise and limits of early detection—from liquid biopsies to at-home pap smears 🌍 The global race for healthcare innovation and why the U.S. can’t afford to fall behind Listen here: Apple: https://lnkd.in/gRkQM9aJ Spotify: https://lnkd.in/gy-C_fBD #EndCancer #NextGenCures #YosemiteFund #CancerResearch #EarlyDetection #DigitalHealth #TheHeartOfHealthcare

We’ve reached a second important R&D milestone in our multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Reaching this second milestone highlights the continued productivity of our collaboration with AbbVie, and reflects the remarkable work of our teams in applying our NxWave™ platform to discover and advance novel molecules that modulate neurological disease targets. Read more here: https://lnkd.in/eFPBNVRx

From Research to Reality: Innovations in Oncology with Feyi Ayodele is one of the HLTH USA sessions I’m most looking forward to. The idea of precision medicine is simple: treat the person, not the average. What’s less simple is the world it creates. Tests that read deeper than ever, therapies designed for smaller and smaller groups, results that don’t line up anymore. In practice, care pathways start to splinter. Some patients move quickly, others get stuck. Data opens doors, but it also exposes cracks we didn’t see before. The science races ahead, while the system struggles to keep pace. #HLTH2025 #PresicionMedicine HLTH Inc.

We’re proud to participate in the 2025 NEALS Annual Meeting in Clearwater, Florida — one of the world’s leading gatherings dedicated to advancing research and care in Amyotrophic Lateral Sclerosis (ALS). This year, Team Neurizon will contribute two scientific posters that highlight both our preclinical research and collaborative innovation: 🧠 Preclinical Characterization of NUZ-001: A Brain-Penetrant Small Molecule That Reduces TDP-43 Aggregation in ALS Models — presented by Dr Jeffrey Brown, Chief Scientific Advisor, showcasing preclinical findings supporting NUZ-001’s potential to address shared disease mechanisms in ALS and other neurodegenerative conditions. 📊 Leveraging External Controls from PRO-ACT for Exploratory Efficacy Assessment in Early-Phase ALS Trials — a collaboration with Berry Consultants, Brigham Young University, and Duke University, and presented by Melanie Quintana, Ph.D, Director Berry Consultants, demonstrating innovative statistical approaches to improve early-phase ALS trial interpretation and design. The NEALS Meeting provides an invaluable opportunity to connect with global experts, patient advocates, and clinical collaborators — including partners from the HEALEY ALS Platform Trial — as we continue to advance science that aims to make a meaningful difference for people living with ALS/MND. 🔗 Learn more about the event: https://meeting.neals.org Reach out to our team on site for a catch-up: Michael Thurn, Sharon Tamir and Jeffrey Brown #NeurizonTherapeutics #NUZ001 #ALS #MND #NeuroDegenerativeDiseases

We’re excited to feature Retsina Meyer, PhD, Head of Corporate Strategy at Delix Therapeutics, in Week 3 of the Future Neuro Founders Program co-hosted by PsyMed Ventures and KdT Ventures. Retsina will guide participants through mapping out the development path from defining timelines and milestones to aligning these with funding rounds. This session will help founders strategically plan their progress from discovery to commercialization, a key skill for anyone building in the neurotech and mental health innovation space. Delix is a Boston-based biotechnology company pioneering a new class of compounds called psychoplastogens, non-hallucinogenic molecules that promote neuroplasticity. Their mission is to harness the therapeutic benefits of psychedelics without the hallucinatory side effects, aiming to treat a range of psychiatric and neurodegenerative disorders including depression, PTSD, and cognitive decline. Apply by Thursday to join a community of neuro founders: https://luma.com/qnc9pdaa

The Children’s Tumor Foundation is proud to invest nearly $1.5 million in a new wave of research tackling the toughest challenges facing NF1 and all forms of schwannomatosis, including NF2-related schwannomatosis. Through our Young Investigator Awards (YIA) program, early-career scientists and clinicians are leading bold projects that address the full spectrum of NF needs—from aggressive tumors and skeletal complications to hearing loss and learning challenges. By bringing cutting-edge science, smarter care, and real solutions to the NF community, these researchers are shaping the future of NF treatments and improving the lives of patients and families around the world. Meet the next generation of NF researchers: https://lnkd.in/eDMsuTk2 #EndNF #RareDiseaseResearch #MedicalInnovation #YoungInvestigatorAwards #NF #NF1 #NF2 #NF2SWN #SWN #neurofibromatosis #schwannomatosis